Recruiting Brain Cancer Studies in Cincinnati
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism h...
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) o...
Study of Ribociclib and Everolimus in HGG and DIPG
The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including D...
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate...
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation...
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG....
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be inef...
About Brain Cancer Clinical Trials in Cincinnati
Brain cancer includes tumors that originate in the brain (primary) or spread from other areas (metastatic). Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Treatment typically combines surgery, radiation, and chemotherapy, with immunotherapy trials underway.
There are currently 7 brain cancer clinical trials recruiting participants in Cincinnati, OH. These studies are seeking a combined 595 participants. Research is being sponsored by Theodore S. Johnson, Nationwide Children's Hospital, Rigel Pharmaceuticals and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Brain Cancer Clinical Trials in Cincinnati — FAQ
Are there brain cancer clinical trials in Cincinnati?
Yes, there are 7 brain cancer clinical trials currently recruiting in Cincinnati, OH. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Cincinnati?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you about next steps.
Are clinical trials in Cincinnati free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cincinnati studies also compensate for your time and travel.
What brain cancer treatments are being tested?
The 7 active trials in Cincinnati are testing new therapies including novel drugs, biologics, and treatment approaches for brain cancer.
Data updated March 2, 2026 from ClinicalTrials.gov